VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Columnist Susan Payrovi credits hand weakness and MS with the pivots in her medical career that now allow her to focus on ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases – by reprogramming patients’ out-of-whack immune ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

In pediatric-onset multiple sclerosis, switching to oral or infusion therapies was linked to fewer relapses than switching between injectable treatments.

Subcutaneous administration of natalizumab provides similar real-world effectiveness to intravenous administration, providing ...

Dr. Arijit Datta explained, “In cases of a heart attack, surgery is rarely required unless complications arise. Usually, ...

Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

People are being urged to consider alternatives before visiting Hull's emergency department after nearly half of Monday's patients had "less serious" cases. Interim group chief nurse of Hull Royal ...

President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

Lupin has received tentative USFDA approval to market generic Siponimod Tablets for treating multiple sclerosis, strengthening its US portfolio in speciality medicines.